<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35046530</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5462</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3-4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Gene therapy</Title><ISOAbbreviation>Gene Ther</ISOAbbreviation></Journal><ArticleTitle>Getting the upper hand in ALS.</ArticleTitle><Pagination><StartPage>113</StartPage><EndPage>114</EndPage><MedlinePgn>113-114</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41434-022-00314-9</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Svendsen</LastName><ForeName>Clive N</ForeName><Initials>CN</Initials><Identifier Source="ORCID">0000-0001-8696-3446</Identifier><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP 8th Floor, Los Angeles, CA, 90048, USA. clive.svendsen@cshs.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UG3 TR003264</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Gene Ther</MedlineTA><NlmUniqueID>9421525</NlmUniqueID><ISSNLinking>0969-7128</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The author declares no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>20</Day><Hour>5</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35046530</ArticleId><ArticleId IdType="pmc">PMC9013663</ArticleId><ArticleId IdType="doi">10.1038/s41434-022-00314-9</ArticleId><ArticleId IdType="pii">10.1038/s41434-022-00314-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gen&#xe7; B, Jara JH, Sanchez SS, Lagrimas AKB, G&#xf6;z&#xfc;tok &#xd6;, Ko&#xe7;ak N, et al. Upper motor neurons are a target for gene therapy and UCHL1 is necessary and sufficient to improve cellular integrity of diseased upper motor neurons. Gene Ther. 2021. Online ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9018479</ArticleId><ArticleId IdType="pubmed">34853443</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, &#xd6;zdinler PH, Kiernan MC, Vucic S. Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nat Rev Neurol. 2016;12:651&#x2013;61. doi: 10.1038/nrneurol.2016.140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.140</ArticleId><ArticleId IdType="pubmed">27658852</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, Gowing G, Latter J, Chen M, Vit JP, Staggenborg K, Avalos P, Alkaslasi M, Ferraiuolo L, Likhite S, Kaspar BK, Svendsen CN. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J Neurosci. 2014;34:15587&#x2013;600. doi: 10.1523/JNEUROSCI.2037-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2037-14.2014</ArticleId><ArticleId IdType="pmc">PMC4298650</ArticleId><ArticleId IdType="pubmed">25411487</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, Avalos P, Ma AA, Alkaslasi M, Cho N, Wyss L, Vit JP, Godoy M, Suezaki P, Shelest O, Bankiewicz KS, Svendsen CN. Transplantation of Neural progenitor cells expressing Glial Cell Line-Derived Neurotrophic Factor into the motor cortex as a strategy to treat Amyotrophic Lateral Sclerosis. Stem Cells. 2018;36:1122&#x2013;31. doi: 10.1002/stem.2825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2825</ArticleId><ArticleId IdType="pubmed">29656478</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A, Braak H, Del Tredici K, Lemon R, Ludolph AC, Kiernan MC. Cortical influences drive amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88:917&#x2013;24. doi: 10.1136/jnnp-2017-315573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315573</ArticleId><ArticleId IdType="pubmed">28710326</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>